Zimberelimab + Domvanalimab + FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adenocarcinoma Stomach
Conditions
Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction
Trial Timeline
Feb 1, 2026 → Dec 1, 2029
NCT ID
NCT07283848About Zimberelimab + Domvanalimab + FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)
Zimberelimab + Domvanalimab + FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel) is a phase 2 stage product being developed by Arcus Biosciences for Adenocarcinoma Stomach. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT07283848. Target conditions include Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07283848 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Adenocarcinoma Stomach